ID   PC-9/GR4
AC   CVCL_DH34
SY   PC-9 GR4; PC9GR4; GR4
DR   cancercelllines; CVCL_DH34
DR   GEO; GSM925738
DR   GEO; GSM481164
DR   Progenetix; CVCL_DH34
DR   Wikidata; Q54938497
RX   PubMed=20118985;
RX   PubMed=22961667;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Iressa).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 13
//
RX   PubMed=20118985; DOI=10.1038/onc.2009.526;
RA   Ercan D., Zejnullahu K., Yonesaka K., Xiao Y., Capelletti M.,
RA   Rogers A., Lifshits E., Brown A., Lee C., Christensen J.G.,
RA   Kwiatkowski D.J., Engelman J.A., Janne P.A.;
RT   "Amplification of EGFR T790M causes resistance to an irreversible EGFR
RT   inhibitor.";
RL   Oncogene 29:2346-2356(2010).
//
RX   PubMed=22961667; DOI=10.1158/2159-8290.CD-12-0103;
RA   Ercan D., Xu C.-X., Yanagita M., Monast C.S., Pratilas C.A., Montero J.,
RA   Butaney M., Shimamura T., Sholl L.M., Ivanova E.V., Tadi M., Rogers A.,
RA   Repellin C., Capelletti M., Maertens O., Goetz E.M., Letai A.G.,
RA   Garraway L.A., Lazzara M.J., Rosen N., Gray N.S., Wong K.-K.,
RA   Janne P.A.;
RT   "Reactivation of ERK signaling causes resistance to EGFR kinase
RT   inhibitors.";
RL   Cancer Discov. 2:934-947(2012).
//